Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epigenomics Deal Gives Roche Access To DNA Methylation Cancer Tests

This article was originally published in The Gray Sheet

Executive Summary

Roche can expect to have DNA methylation-based cancer screening assays available to reference labs by 2006 under a collaboration with Epigenomics

You may also be interested in...



Affymetrix GeneChip Arrays Elevated In Roche Pact, Considered By FDA

Affymetrix' plans to establish its GeneChip as the standard platform technology for genomics-based diagnostics are bolstered by FDA enthusiasm for the probe microarrays, the company claims

Flu Vaccine Leader Sanofi Joins Fight Against Covid-19

As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.

Sobi Reaps Benefits From Acquisitions, Commercial Focus

Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.

  

UsernamePublicRestriction

Register

MT018081

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel